Supplementary Table 1. Distribution of baseline and final eGFRa in treatment naïve PLWH, CNICS cohort (2007-2014)

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Baselineb eGFR,  (mL/min/1.73m2) | Finalc eGFR (mL/min/1.73m2) | | | | Total |
|  | <30 | ≥30 to <45 | ≥45 to <60 | ≥60 |  |
|  | n (%) | n (%) | n (%) | n (%) | N (%) |
| <30 | 34 (0.8) | 3 (0.1) | 2 (0.04) | 2 (0.04) | 41 (0.9) |
| ≥30 to <45 | 7 (0.2) | 8 (0.2) | 4 (0.1) | 10 (0.2) | 29 (0.6) |
| ≥45 to <60 | 3 (0.1) | 8 (0.2) | 24 (0.5) | 23 (0.5) | 58 (1.3) |
| ≥60 | 14 (0.3) | 27 (0.6) | 94 (2.1) | 4252 (94.2) | 4387 (97.2) |
|  |  |  |  |  |  |
| Total (%) | 58 (1.3) | 46 (1.0) | 124 (2.7) | 4287 (95.0) | 4515 |

ART=anti-retroviral therapy; CNICS=CFAR Network of Integrated Clinical Systems; GFR=glomerular filtration rate; PLWH=People living with HIV.

NOTE: The percentages are calculated using the denominator of N=4515.

aKidney dysfunction expressed as an estimated Glomerular filtration rate (eGFR) using the Chronic Kidney Disease Epidemiology Collaboration equation.6

bAt the initiation of anti-retroviral therapy (within 180 days).

cMost proximate (but within 180 days) to modifying ART (first regimen)for those with an event and before the censoring date for those who did not modify ART over the study.

Supplementary Table 2. Univariate and multivariable analyses examining hazard ratios for regimen modification within final eGFR strata in treatment naïve PLWH, CNICS cohort (2007-2014)

|  |  |  |  |
| --- | --- | --- | --- |
| Type of analysis | Final eGFRa (mL/min/1.73m2) | | |
|  | <45 (N=104) | 45 to <60 (N=124) | ≥60 (N=4287) |
|  |  |  |  |
| Regimen modified, n (%) | 71 (68.3) | 65 (52.4) | 1831 (42.7) |
|  |  |  |  |
| Univariate,b HR (95 % CI) | 0.80 (0.50 – 1.29) | 0.97 (0.54 – 1.74) | 0.45 (0.40 – 0.51) |
| p-value | 0.36 | 0.90 | <0.001 |
|  |  |  |  |
| Multivariable,b,c HR (95 % CI) | 0.82 (0.42 – 1.63) | 1.26 (0.63 – 2.48) | 0.47 (0.41 – 0.53) |
| p-value | 0.58 | 0.51 | <0.001 |

CI=Confidence interval; CNICS=CFAR Network of Integrated Clinical Systems; HR=Hazard ratio; PLWH=People living with HIV; TDF=Tenofovir disoproxil fumarate.

aKidney dysfunction expressed as an estimated Glomerular filtration rate (eGFR) using the Chronic Kidney Disease Epidemiology Collaboration equation.6 Final eGFR most proximate (but within 180 days) to modifying ART (first regimen) was identified for those with an event and before the censoring date for those who did not modify ART over the study.

bCox proportional hazard analysis comparing regimens: TDF vs Other (reference category).

cAlso adjusted for confounders: baseline (at regimen initiation) values of GFR at regimen initiation, age, sex, race, viral load (at regimen initiation), and CD4 count (regimen initiation).